Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximab, Brentuximab Vedotin, Alemtuzumab, and Mogamulizumab.

Publikation: Beitrag in Buch/Bericht/Konferenzband › Kapitel › Begutachtung

Originalsprache	Englisch
Titel	Adverse Reactions to Biologics
Seiten	70-81
Seitenumfang	12
Band	53
DOIs	https://doi.org/10.1159/000478079
Publikationsstatus	Veröffentlicht - 2018

Name	Current Problems in Dermatology (Switzerland)
ISSN (Print)	1421-5721

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

@inbook{2fcc60c13eb94b9898aaf14912cf74b3,

title = "Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximab, Brentuximab Vedotin, Alemtuzumab, and Mogamulizumab.",

author = "I. Saulite and Emmanuella Guenova and Wolfram H{\"o}tzenecker",

year = "2018",

doi = "10.1159/000478079",

language = "English",

volume = "53",

series = "Current Problems in Dermatology (Switzerland)",

pages = "70--81",

booktitle = "Adverse Reactions to Biologics",

}

Publikation: Beitrag in Buch/Bericht/Konferenzband › Kapitel › Begutachtung

TY - CHAP

T1 - Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximab, Brentuximab Vedotin, Alemtuzumab, and Mogamulizumab.

AU - Saulite, I.

AU - Guenova, Emmanuella

AU - Hötzenecker, Wolfram

PY - 2018

Y1 - 2018

UR - https://www.ncbi.nlm.nih.gov/pubmed/29131039

UR - https://www.scopus.com/pages/publications/85033468467

U2 - 10.1159/000478079

DO - 10.1159/000478079

M3 - Chapter

VL - 53

T3 - Current Problems in Dermatology (Switzerland)

SP - 70

EP - 81

BT - Adverse Reactions to Biologics

ER -